Development of a Radiopharmaceutical using 166Ho-chitosan Complexes against Prostate Cancer

  • Published : 2003.04.01

Abstract

166Ho-chitosan complex (HC) is a new radiopharmaceutical approved in Korea for liver cancer. In these studies, therapeutic effect against prostate cancer and biodistribution of HC were evaluated in animal models using the technique of intraprostatic administration. For evaluation of the therapeutic effect, noble rats with AIT orthotopic or subcutaneous prostate cancer were used. (omitted)

Keywords